Myovant Sciences Ltd. Daily Stock Analysis

Daily Stock Analysis, MYOV, Myovant Sciences Ltd, priceseries

Myovant Sciences Ltd. Daily Stock Analysis
Stock Information
Open
12.05
Close
11.43
High
12.24
Low
11.42
Previous Close
12.06
Daily Price Gain
-0.63
YTD High
16.69
YTD High Date
Jan 3, 2022
YTD Low
11.32
YTD Low Date
Feb 24, 2022
YTD Price Change
-4.97
YTD Gain
-30.30%
52 Week High
27.43
52 Week High Date
Sep 7, 2021
52 Week Low
11.32
52 Week Low Date
Feb 24, 2022
52 Week Price Change
-10.68
52 Week Gain
-48.30%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Apr 13. 2017
11.49
May 3. 2017
12.32
13 Trading Days
7.20%
Link
LONG
May 23. 2017
12.42
Jun 7. 2017
13.88
10 Trading Days
11.74%
Link
LONG
Aug 17. 2017
11.53
Aug 30. 2017
13.28
9 Trading Days
15.15%
Link
LONG
Jan 3. 2018
12.51
Jan 16. 2018
13.29
8 Trading Days
6.21%
Link
LONG
Mar 1. 2018
14.55
Apr 10. 2018
20.14
27 Trading Days
38.45%
Link
LONG
Aug 22. 2018
21.49
Sep 5. 2018
23.07
9 Trading Days
7.36%
Link
LONG
Feb 12. 2019
19.19
Mar 8. 2019
21.70
17 Trading Days
13.08%
Link
LONG
Mar 18. 2019
22.51
Apr 8. 2019
23.65
15 Trading Days
5.08%
Link
LONG
Nov 21. 2019
12.43
Dec 9. 2019
16.22
11 Trading Days
30.51%
Link
LONG
Apr 8. 2020
8.75
May 1. 2020
11.22
16 Trading Days
28.22%
Link
LONG
Jun 22. 2020
17.41
Jul 7. 2020
19.55
10 Trading Days
12.27%
Link
LONG
Nov 9. 2020
15.42
Dec 14. 2020
24.29
24 Trading Days
57.49%
Link
LONG
May 11. 2021
19.76
Jun 11. 2021
23.15
22 Trading Days
17.18%
Link
LONG
Aug 25. 2021
22.37
Sep 10. 2021
24.54
11 Trading Days
9.69%
Link
Company Information
Stock Symbol
MYOV
Exchange
NYSE
Company URL
http://www.myovant.com
Company Phone
-
CEO
Lynn Seely
Headquarters
-
Business Address
-
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
-
About

Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company. It specializes in development and commercialization of innovative therapies for women's health diseases and other endocrine-related disorders. It focuses on product candidate, relugolix, for the treatment of heavy menstrual bleeding associated with uterine fibroids, endometriosis-associated pain and advanced prostate cancer, as well as in RVT-602, for the treatment of female infertility as part of assisted reproduction. The company was founded on February 2, 2016 and is headquartered in Hamilton, Bermuda.

Description

Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health diseases and other endocrine-related disorders. Its lead product candidate is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist, for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. The company also intends to develop RVT-602, an oligopeptide kisspeptin analog, for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. was founded in 2016 and is based in Hamilton, Bermuda. Myovant Sciences Ltd. operates as a subsidiary of Roivant Sciences Ltd.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading